Literature DB >> 8515384

Deficits of the automatic orienting of attention in schizophrenic patients.

M Liotti1, S Dazzi, C Umiltà.   

Abstract

The automatic orienting of attention was studied in medicated non-psychotic schizophrenic patients and in matched controls using the Posner paradigm of covert orienting to peripheral cues. This paradigm allows determination of the "benefits" in performance when attention is moved in advance to target location ("valid" trials) and the "costs" in performance when attention has to be reoriented to target location after an incorrect directional cue ("invalid" trials). Compared to normals, schizophrenics showed reduced costs of invalid cueing and increased benefits of valid directional cueing. Schizophrenics did not show selective visual field asymmetries reported in similar studies. The decreased inhibition in the presence of incorrect directional cues may be related to a reduced tone of monoaminergic terminals possibly involved in the regulation of selective attention and arousal regulation.

Entities:  

Mesh:

Year:  1993        PMID: 8515384     DOI: 10.1016/0022-3956(93)90056-8

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  10 in total

1.  Hyperdeactivation of the Default Mode Network in People With Schizophrenia When Focusing Attention in Space.

Authors:  Britta Hahn; Alexander N Harvey; James M Gold; Bernard A Fischer; William R Keller; Thomas J Ross; Elliot A Stein
Journal:  Schizophr Bull       Date:  2016-02-28       Impact factor: 9.306

2.  Enhanced facilitation of spatial attention in schizophrenia.

Authors:  Kevin M Spencer; Paul G Nestor; Olga Valdman; Margaret A Niznikiewicz; Martha E Shenton; Robert W McCarley
Journal:  Neuropsychology       Date:  2011-01       Impact factor: 3.295

3.  Visuospatial attention in schizophrenia: deficits in broad monitoring.

Authors:  Britta Hahn; Benjamin M Robinson; Alexander N Harvey; Samuel T Kaiser; Carly J Leonard; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2011-05-23

4.  Hyperfocusing in schizophrenia: Evidence from interactions between working memory and eye movements.

Authors:  Steven J Luck; Clara McClenon; Valerie M Beck; Andrew Hollingworth; Carly J Leonard; Britta Hahn; Benjamin M Robinson; James M Gold
Journal:  J Abnorm Psychol       Date:  2014-08-04

5.  Altered spatial profile of distraction in people with schizophrenia.

Authors:  Carly J Leonard; Benjamin M Robinson; Britta Hahn; Steven J Luck; James M Gold
Journal:  J Abnorm Psychol       Date:  2017-11

6.  The construct of attention in schizophrenia.

Authors:  Steven J Luck; James M Gold
Journal:  Biol Psychiatry       Date:  2008-03-28       Impact factor: 13.382

7.  Pharmacological modulation of the neural basis underlying inhibition of return (IOR) in the human 5-HT2A agonist and NMDA antagonist model of psychosis.

Authors:  Jörg Daumann; Karsten Heekeren; Anna Neukirch; Christiane M Thiel; Walter Möller-Hartmann; Euphrosyne Gouzoulis-Mayfrank
Journal:  Psychopharmacology (Berl)       Date:  2008-07-24       Impact factor: 4.530

8.  Auditory orienting and inhibition of return in schizophrenia: a functional magnetic resonance imaging study.

Authors:  Christopher C Abbott; Flannery Merideth; David Ruhl; Zhen Yang; Vincent P Clark; Vince D Calhoun; Faith M Hanlon; Andrew R Mayer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-12-30       Impact factor: 5.067

9.  Fragile temporal prediction in patients with schizophrenia is related to minimal self disorders.

Authors:  Brice Martin; Nicolas Franck; Michel Cermolacce; Agnès Falco; Anabel Benair; Estelle Etienne; Sébastien Weibel; Jennifer T Coull; Anne Giersch
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

10.  Fragmented perception: slower space-based but faster object-based attention in recent-onset psychosis with and without Schizophrenia.

Authors:  Henderikus G O M Smid; Richard Bruggeman; Sander Martens
Journal:  PLoS One       Date:  2013-03-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.